Home > Patent Portfolio
Getting Lost in the Thicket: AbbVie Wields Its Expansive Humira® Patent Portfolio Against Alvotech’s Adalimumab Biosimilar
Rothwell Fig logo 1 | International Network of Boutique and Independent Law Firms

Author: Andrew J. StoraskaPublished: June 24, 2021In the most recent of a series of litigations by AbbVie against manufacturers seeking to market biosimilar versions of Humira®, the world’s most profitable drug, AbbVie initiated an action against Alvotech in the district court for the Northern District of Illinois on April 27, 2021,

Read More
Rothwell Fig, biosimilars, AbbVie